4564.T OncoTherapy Science JPX pre-market 05 Feb 2026: Q4 results and key catalysts

In pre-market trade on 05 Feb 2026, 4564.T stock is steady at JPY 20.00 as investors parse the company’s recent earnings timing and clinical updates. The biotech’s market cap is JPY 6,872,871,920.00 and average daily volume sits near 51,384,668.00 shares. Trailing EPS is -2.83 and PE reads -7.07, underscoring continued negative earnings. We focus on how clinical milestones and the latest results could shift valuation for JPX-listed OncoTherapy Science, Inc.

4564.T stock: Earnings snapshot and clinical pipeline

OncoTherapy Science reports an earnings announcement dated 04 Feb 2026 that investors are still digesting. The company runs multiple oncology programs, including S-588410 (Phase III) and small-molecule candidates OTS167 and OTS964 in early-stage trials. Clinical readouts and licensing updates typically drive large intraday moves in this name on the JPX.

Financial metrics and valuation for 4564.T stock

At JPY 20.00, price sits below the 50-day average of JPY 21.08 and the 200-day of JPY 24.24. Price-to-sales is 7.18, price-to-book is 3.87, and current ratio is 8.63, signalling strong liquidity but weak profitability. Net income per share is -2.59, while R&D is 53.91% of revenue, reflecting heavy development spending that investors must weigh.

Meyka Grade & valuation

Meyka AI rates 4564.T with a score out of 100: 65.48, Grade B, HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst signals, and industry trends. The internal grade highlights a middling risk/reward profile versus larger healthcare peers on JPX.

Technical view and trading setup for 4564.T stock

Technically, momentum indicators show strength; RSI is 68.81 and MACD histogram is 0.40, but ADX at 14.99 signals no clear trend. Bollinger bands run JPY 19.00–23.10, so a breakout above JPY 23.10 would be a near-term bullish signal. Average volume remains elevated at 36,753,100.00 shares, supporting higher intraday volatility.

Risks, catalysts and sector context

Primary risk remains clinical and regulatory outcomes for lead programs; failures would hit valuation sharply. Catalysts include Phase III milestones, partnership or licensing deals, and updated guidance from management. Healthcare peers on JPX show modest YTD gains, leaving OncoTherapy exposed to both sector momentum and company-specific binary events.

Analyst sentiment, price targets and trading notes

Official sell-side consensus is sparse and no price-target consensus exists publicly. Meyka AI input and technicals suggest a cautious trading approach and shorter position sizing for speculative entries. For longer-term investors, conserved cash buffers make sense given negative earnings and pipeline risk.

Final Thoughts

Key takeaways: 4564.T stock trades at JPY 20.00 after an earnings event window and remains driven by clinical milestones. Fundamentals show strong liquidity with a current ratio of 8.63, but persistent net losses and a negative EPS of -2.83 weigh on valuation. Meyka AI’s forecast model projects a monthly price of JPY 22.55 and a yearly price of JPY 18.27. Compared with the current price of JPY 20.00, the monthly forecast implies an upside of +12.75%, while the yearly forecast implies a downside of -8.63%. Meyka AI’s projections are model-based and not guarantees. Investors should weigh binary clinical risk, limited analyst coverage, and JPX healthcare sector trends before sizing positions. For up-to-date filings and company statements see the Reuters company page and our Meyka stock hub for 4564.T

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.